<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=4423596&amp;fmt=gif">
Discover AGCellerate™ for LVV - a faster option to get your GMP-ready lentiviral vector product   Learn about AGCellerate

1 min read

Gene Therapy for Rare Disorders Europe, Oct 25-27, 2022

Gene Therapy for Rare Disorders Europe, Oct 25-27, 2022

Date: October 25-27, 2022
Location: London, England
Event Website: genetherapy-europe.com
Organizer: Hanson Wade

Meet with our Team Members

Contact us to schedule a meeting

About our Cell & Gene Therapy Services

We develop and manufacture diverse cell therapies including CD34+ hematopoietic stem cells, autologous and allogenic T-cells, and NK cells. Our cell therapy capabilities cover numerous technologies, ranging from closed to open systems at different scales, depending on client needs. We also develop and manufacture adeno-associated viral vectors, lenti viral vectors and retro viral vectors. Our ready-to-use platform capabilities are built on cell factories (up to 48L) and bioreactors (up to 200L) using adherent processes, designed entirely in-house. 

Learn more about our Cell Therapy and Viral Vector services

About the Event

This year’s summit is dedicated to gaining European regulatory clarity to progress efficient and robust gene therapies for rare diseases. By giving voice to pioneering drug developers with success stories to share, experts in regulatory affairs, and the regulators themselves, this meeting is your comprehensive guide to unpicking the thorniest regulatory challenges.

Across three carefully curated days, this streamlined one-track summit will unite key gene therapy leaders from large pharma to ground-breaking biotech, academics to exciting service providers, all with the purpose of paving a way forward to successfully launch gene therapy products in Europe.